Hims & Hers Health

HIMS

Market cap $3.31B

HIMS expands into labs, cancer screening, menopause and global markets, advancing its digital, subscription-driven healthcare platform and preventive care.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces it is investigating potential claims against the board of directors of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) concerning whether the board breached its fiduciary duties to shareholders. IF YOU ARE A HIMS & HERS HEALTH, INC. (HIMS) SHAREHOLDER, CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howard.

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Hims stock has been under pressure this year. The company turned in solid Q4 results, but issued soft Q1 guidance.

Hims & Hers offers direct-to-consumer healthcare in a digitally native manner. The company is profitable, and its subscriber base is growing.

Hims & Hers Health stock beat on earnings but suffered a steep sales slowdown in Q4. Hims & Hers is trying to figure out how to grow without selling GLP-1 drugs.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) concerning whether the board breached its fiduciary duties to shareholders. If you are a shareholder, click here to participate. On February 7, 2026, The New York Times reported that the Company would stop selling its version of Wegovy, a popular weight loss drug by competitor Novo Nordisk. A former.

Hims & Hers and Amwell are taking different paths in telehealth, but which stock offers the stronger opportunity today? Let's dive in.

Hims & Hers Health, Inc. is facing existential risk as regulatory uncertainty and margin erosion undermine its growth narrative. HIMS' reliance on compounded GLP-1 drugs has faltered, with regulatory headwinds and an SEC investigation clouding visibility and investor trust. Despite solid subscriber and revenue growth, margin compression and weak guidance highlight unsustainable marketing intensity and operational risks.

Hims & Hers Health, Inc. remains ultra Bullish despite a near 80% drawdown from 52-week highs, with growth initiatives firmly on track. HIMS projects 2026 revenues of $2.7–$2.9 billion, above consensus, and expects strong subscriber growth in weight loss offerings despite temporary GLP-1 headwinds. The Eucalyptus acquisition is set to add at least $200 million to 2026 revenues, positioning HIMS for a $3.25–$4 billion annualized run rate entering 2027.